From UroToday.com: Ablatherm® - HIFU: A New Perspective in 2007, the Year of the First Long Term Clinical Results on the Treatment of Localised Prostate Cancer
From UroToday.com: Ablatherm® - HIFU: A New Perspective in 2007, the Year of the First Long Term Clinical Results on the Treatment of Localised Prostate Cancer
The clinical results are presented as follows:
- Ablatherm® Long Term Results As A Salvage Option After Radiotherapy Failure
By Pr. G. Conti MD, Como, Italy - Ablatherm® Efficiency on Long Term Results
By F.J. Murat MD, Lyon, France - Ablatherm® Safety on Long Term Results
By A. Blana MD, Regensburg, Germany - PSA Nadir: A Surrogate Marker Of Long-Term Efficacy in HIFU Therapy Localised Prostate Cancer
By S. Brown MD, Stockport, UK
Visit the HIFU Resource Center and stay updated on clinical developments in HIFU and Prostate Cancer.
About UroToday UroToday.com attracts more than 45,000 readers monthly. The website covers over 22 urology disease categories and provides the most in depth Urological conference reports available online. UroToday.com is the world leader in delivering a quality, global online publication providing accurate and timely education that is clinically relevant in the practice of Urology. All scientific content is developed by urologists committed to translating research into clinically relevant science, including all genitourinary cancers, pediatric and geriatric urological dysfunctions for urologists, medical oncologists, advanced nurse practitioners and other medical professionals.
Contact:
Gina Carithers
Publisher, UroToday.com
' );
document.write( addy73634 );
document.write( '<\/a>' );
//-->
publisher@urotoday.com
' );
//-->
' );
//-->